In the wake of the HHS Office of Inspector General's 2013 findings that FDA failed to identify ways to evaluate whether manufacturers are complying with Risk Evaluation and Mitigation Strategies, OIG is now investigating FDA's oversight of REMS specifically for opioids. An OIG spokesperson tells Inside Health Policy the report is part of OIG's wider look at opioids and was not undertaken due to a congressional request. The move comes on the heels of Commissioner Scott Gottlieb's recent announcement...